AB
FDMT icon

Amalgamated Bank’s 4D Molecular Therapeutics FDMT Stock Holding History

Amalgamated Bank’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,261
Closed -$9K – 2036
2025
Q4 		$9K Sell
1,261
-477
-27% -$4.84K ﹤0.01% 2463
2025
Q3 		$15K Hold
1,738
– – ﹤0.01% 2264
2025
Q2 		$6K Hold
1,738
– – ﹤0.01% 2647
2025
Q1 		$6K Buy
1,738
+375
+28% +$1.77K ﹤0.01% 2580
2024
Q4 		$8K Hold
1,363
– – ﹤0.01% 2537
2024
Q3 		$15K Hold
1,363
– – ﹤0.01% 2248
2024
Q2 		$29K Hold
1,363
– – ﹤0.01% 1993
2024
Q1 		$43K Sell
1,363
-2,486
-65% -$63.4K ﹤0.01% 1902
2023
Q4 		$78K Sell
3,849
-55
-1% -$724 ﹤0.01% 2084
2023
Q3 		$50K Buy
3,904
+652
+20% +$10.9K ﹤0.01% 2251
2023
Q2 		$59K Buy
3,252
+80
+3% +$1.47K ﹤0.01% 2253
2023
Q1 		$55K Sell
3,172
-615
-16% -$12K ﹤0.01% 2269
2022
Q4 		$84K Buy
3,787
+90
+2% +$1.39K ﹤0.01% 2197
2022
Q3 		$30K Hold
3,697
– – ﹤0.01% 2671
2022
Q2 		$26K Buy
3,697
+202
+6% +$1.96K ﹤0.01% 2782
2022
Q1 		$53K Buy
+3,495
New +$54.9K ﹤0.01% 2452

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Amalgamated Bank's FDMT Position: Q1 2026 in Review

Amalgamated Bank sold out of 4D Molecular Therapeutics (FDMT) in Q1 2026, closing a stake of 1,261 shares — an estimated $9K sold.

Amalgamated Bank first reported a position in FDMT in Q1 2022 and held it in 16 quarters. The position peaked at $84K in Q4 2022. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Amalgamated Bank reported no remaining 4D Molecular Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 1,261 4D Molecular Therapeutics shares in Q1 2026, an estimated $9K.
  • Amalgamated Bank first reported a position in 4D Molecular Therapeutics in Q1 2022 and held it in 16 quarters.
  • Amalgamated Bank's 4D Molecular Therapeutics position peaked at $84K in Q4 2022.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.